Drug intelligence / Profile preview

MDX-303

Development stage: Preclinical
Lead developer: VesiCURE Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MDX-303 is an exosome-based therapeutic developed by VesiCURE Therapeutics using its proprietary modEXO technology. It is being investigated primarily for the treatment of COVID-19 infections and other respiratory diseases, with a focus on lung diseases. The precise mechanism of action has not been defined or disclosed publicly. As an exosome therapy, it likely leverages extracellular vesicles to deliver therapeutic effects, potentially through immunomodulation or delivery of bioactive molecules, but specific targets and pathways remain unspecified. The drug is currently in preclinical development and has not yet entered clinical trials[1][2].

Other names: MDX 303MDX303MDX-303

Beyond the preview

Go deeper on MDX-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX-303.

Explore the full profile